Cookson Peirce & Co. Inc. Purchases 7,168 Shares of Gilead Sciences, Inc. $GILD

Cookson Peirce & Co. Inc. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 249.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 10,045 shares of the biopharmaceutical company’s stock after purchasing an additional 7,168 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Gilead Sciences were worth $1,115,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GILD. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Corundum Trust Company INC bought a new position in Gilead Sciences in the 3rd quarter worth $26,000. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences in the 2nd quarter worth $27,000. Howard Hughes Medical Institute bought a new stake in Gilead Sciences during the second quarter valued at about $30,000. Finally, Putney Financial Group LLC raised its holdings in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 2.1%

GILD stock opened at $154.98 on Friday. The firm has a fifty day moving average price of $130.27 and a 200 day moving average price of $122.27. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The firm has a market cap of $192.28 billion, a PE ratio of 22.89, a price-to-earnings-growth ratio of 1.22 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the business earned $1.90 earnings per share. Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is 46.68%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the chief financial officer owned 150,503 shares in the company, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. This represents a 16.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 319,391 shares of company stock worth $44,141,101. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Bank of America set a $162.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday. Citigroup boosted their price target on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. Oppenheimer lifted their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, UBS Group boosted their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Twenty-three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $152.42.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post‑earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short‑interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.